Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationMultiple MyelomaMelphalanTransplantation, HomologousTransplantation ConditioningLymphomaLymphoma, Non-HodgkinCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsRemission InductionTreatment OutcomeStem CellsSalvage TherapyHodgkin DiseaseDisease-Free SurvivalEtoposideMyeloablative AgonistsRecurrenceCyclophosphamideCytarabineLymphoma, B-CellLymphoma, Mantle-CellLymphoma, FollicularVincristineCarmustineGraft vs Host DiseaseHematopoietic Stem Cell MobilizationBone Marrow TransplantationSurvival RateLymphoma, Large B-Cell, DiffuseBone Marrow PurgingThiotepaHematologic NeoplasmsRetrospective StudiesSurvival AnalysisWhole-Body IrradiationLymphoma, T-Cell, PeripheralAmyloidosisHematopoietic Stem CellsBoronic AcidsBusulfanAntibodies, Monoclonal, Murine-DerivedPyrazinesDexamethasoneGraft SurvivalPrognosisDoxorubicinAutograftsAntigens, CD34Follow-Up StudiesLiver TransplantationPrednisoneAntineoplastic Agents, AlkylatingThalidomideMesenchymal Stem Cell TransplantationIfosfamideLeukapheresisLymphoma, T-CellPodophyllotoxinTime FactorsGranulocyte Colony-Stimulating FactorTransplantation ChimeraInduction ChemotherapyNeoplasm, ResidualTissue DonorsMaintenance ChemotherapyCord Blood Stem Cell TransplantationAntineoplastic AgentsCell TransplantationEnteropathy-Associated T-Cell LymphomaLeukemia, Myeloid, AcuteKidney TransplantationEmbryonic Stem CellsMyelodysplastic SyndromesLymphoma, AIDS-RelatedLeukemia, Plasma CellInfusions, SpinalIdarubicinNeoplasms, Second PrimaryMitoxantroneAdult Stem CellsBlood Component RemovalImmunosuppressive AgentsHistocompatibility TestingAntibodies, MonoclonalProspective StudiesFatal OutcomeCell DifferentiationRadioimmunotherapyKeratins, Type IIFeasibility StudiesLeukemia, MyeloidLeukemiaHistocompatibilityMesenchymal Stromal CellsBurkitt LymphomaLife Tables